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Abstract
The case-control design is often used to test associations between
the case-control status and genetic variants. In addition to this pri-
mary phenotype a number of additional traits, known as secondary
phenotypes, are routinely recorded and typically associations between
genetic factors and these secondary traits are studied too. Analysing
secondary phenotypes in case-control studies may lead to biased genetic
effect estimates, especially when the marker tested is associated with
the primary phenotype and when the primary and secondary pheno-
types tested are correlated. Several methods have been proposed in the
literature to overcome the problem but they are limited to case-control
studies and not directly applicable to more complex designs, such as the
multiple-cases family studies. A proper secondary phenotype analysis,
in this case, is complicated by the within families correlations on top of
the biased sampling design. We propose a novel approach to accommo-
date the ascertainment process while explicitly modelling the familial
relationships. Our approach pairs existing methods for mixed-effects
models with the retrospective likelihood framework and uses a mul-
tivariate probit model to capture the association between the mixed
type primary and secondary phenotypes. To examine the efficiency
and bias of the estimates we performed simulations under several sce-
narios for the association between the primary phenotype, secondary
phenotype, and genetic markers. We will illustrate the method by
analysing the association between triglyceride levels and glucose (sec-
ondary phenotypes) and genetic markers from the Leiden Longevity
study, a multiple-cases family study that investigates longevity.
Keywords: Ascertainment; Multivariate probit model; Family data; Mixed
models; Genetic association and heritability.
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1 Introduction
In order to understand biological mechanisms underlying disease and health,
epidemiological studies measure genetic markers, classical variables, and
novel omics datasets and model the relationship between these variables
and the phenotype of interest. Here we consider outcome dependent sam-
pling designs with binary outcome variables. In addition to studying these
binary (primary) phenotypes, the classical or omics variables are typically
also analysed as outcome variables (secondary phenotypes). For example
modelling of associations between these traits and genetic factors, such as
single-nucleotide polymorphisms (SNPs) or polygenic risk scores (sumscores
based on SNPs)[1]. However, an important complication which is often ig-
nored is that a proper analysis of the secondary traits should correct for the
sampling mechanism on the primary phenotype (Figure 1). In our motivat-
ing case study, the Leiden Longevity study (LLS)[2] families with at least two
long-lived siblings are recruited. Obviously, these families do not represent
a random sample from the population and inferences cannot be general-
ized to the whole population, unless the sampling mechanism is properly
modelled. Several datasets are measured in the offspring of the long-lived
siblings, namely lipidomics, glycomics, metabolomics, and imaging. These
offspring share a part of their genetic variation with the long-lived parent
and therefore are expected to represent a healthy subpopulation while the
partners represent the population. As data example we will model the effect
of genetic factors on the secondary traits glucose and triglyceride levels in
the offspring (cases) and their partners (controls). To be able to extrap-
olate results to the general population, we need to account for the over
sampling of long-lived subjects in the families of the LLS. There are sev-
eral multiple-case family studies. For human longevity, GEHA (Genetics of
Healthy aging)[3] used the same study design as the LLS. Other examples
are Genetics in Familial Thrombosis (GIFT with at least two cases with
thrombosis) [4, 5] and the ongoing study from Leiden Family Lab (fam-
lab: https://www.leidenfamilylab.nl) which recruits families with at least
two cases with social anxiety disorder. The novel methods presented in this
paper will also be essential for modelling secondary phenotypes in these
studies.
In the context of case-control studies Monsees et al.[6] showed that bias
can occur when estimating the SNP effect on secondary phenotypes if the
primary and secondary phenotypes are associated. This is often the case
because both outcomes are measured on the same subjects and secondary
phenotypes are typically chosen for their potential associations with the
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primary phenotype. They also showed that the amount of bias is dependent
on the prevalence of the primary phenotype, the strength of the association
between the primary and secondary phenotypes, and the association between
the tested marker and the primary trait (see Figure 1).
To deal with the bias problem, investigators first used ad hoc methods
i.e. using controls only, cases only, combined data of cases and controls
or joint analysis of cases and controls adjusting for the case-control sta-
tus. However, several authors showed that these simple approaches can
lead to false positive results [6, 7, 8]. This is due to the sampling design,
namely, the secondary phenotype data are not sampled according to the
case-control design as the primary phenotype. Several sophisticated method-
ologies have been developed to correct for the sampling mechanisms and pro-
vide unbiased genetic effect estimates: (i) inverse-probability-of-sampling-
weighting approaches [6, 9, 10] which correct for the sampling mechanism
by weighting appropriately individuals in case-control studies, (ii) retrospec-
tive likelihood-based approaches which indirectly adjust for ascertainment
[8, 11], and (iii) a weighted combination of two estimates obtained with the
retrospective likelihood approach in the presence or not of an interaction
between SNPs and primary phenotypes [12].
Even though these approaches can successfully correct for the biased
design used to collect the data, they are not directly applicable to more
complex designs such as the LLS which motivates this work. In particular,
inverse probability weighting approaches require knowledge of the sampling
weights for each family. These weights are not available for the LLS be-
cause it is unknown what the prevalence of families with at least two nona-
genarians is in the population. In addition, the correlations between the
family members cannot be ignored and therefore it is evident that statisti-
cal methodology for proper secondary phenotypes analysis in this context
is needed. To this end, under the retrospective likelihood framework, we
develop a multivariate probit regression model inspired by the work of Na-
jita et al.[13] to model jointly the distribution of the primary and secondary
phenotype. This approach allows us to deal with the ascertainment issue
while taking into account the individual relatedness and the genetic and
environmental variations.
The paper is organised as follows: in Section 2, we present the retro-
spective likelihood approach to correct for the over sampling of long-lived
subjects and the multivariate probit regression model for the joint mod-
elling of the mixed type primary and secondary phenotypes. In Section 3,
we evaluate empirically the performance of the method in terms of bias and
efficiency and contrast it with the naive approach which ignores the sampling
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mechanism. Finally, in Section 4 we illustrate the potential of our proposed
method in the analysis of triglyceride levels and glucose in the LLS.
2 Methods
2.1 Retrospective likelihood approach
Let N be the total number of families in the study. For the family i (i =
1 . . . N) of size ni, let Yi, Xi and Gi be the ni×1 vectors for the case-control
status, the secondary phenotype and the genotype, respectively. Motivated
by the LLS, we will work under the retrospective likelihood approach to
correct for the ascertainment of the families. Such an approach is attractive
when modelling the ascertainment mechanism is not straightforward, as in
the LLS where sampling depends on the previous generation (an example of
a pedigree in LLS is shown in Figure 4). In fact the retrospective likelihood
approach implicitly corrects for the ascertainment mechanism, under the
assumption that the ascertainment depends only on the primary phenotype
Y . In particular, for the ith family it holds:
P (Xi, Gi | Yi, Asc) = P (Asc | Yi, Gi,Xi)P (Gi,Xi | Yi)
P (Asc | Yi) = P (Xi, Gi | Yi) ,
(1)
with Asc the ascertainment process. By applying Bayes rule we obtain:
P (Xi, Gi | Yi) = P (Xi, Yi | Gi)P (Gi)
P (Yi)
=
P (Xi, Yi | Gi)P (Gi)∑
g∈G P (Yi | g)P (g)
. (2)
To fully specify (2) we need to model properly: the marginal joint distribu-
tion of the primary phenotype with the secondary phenotype P(Xi, Yi | Gi),
the marginal probability of the primary phenotype P(Yi | Gi), and the geno-
type probability of the ith family P(Gi). Each one of these elements are
described in Sections 2.2 and 2.3.
2.2 Mixed-effects models for the analysis of family data
To model the correlation of the phenotypes Y and X within families, a
common choice is to use random effects. For the binary primary pheno-
type we propose to use a multivariate probit model with random effects.
The advantage of this model is that it involves only the integrals of the
multivariate normal cumulative distribution function for which efficient al-
gorithms have been developed. In contrast, for the more commonly used
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logistic regression model, the integrals have to be approximated for exam-
ple by using Gauss-Hermite quadrature which might be computationally
intensive for large pedigrees. Let bYi =
(
bYi1, . . . , b
Y
ini
)T
be a set of family
specific random effects designed to handle familial genetic correlation and
Gi = (gi1, . . . , gini)
T be the vector of genotypes for family i. For the probit
model, the observed response Y is viewed as a censored observation from an
underlying continuous latent variable Y ∗ with:
Yij = yij ⇔ γyij < Y ∗ij < γyij+1, Yij ∈ {0, 1},
where −∞ =γ0 < γ1 < γ2 = +∞ are suitable threshold parameters. For the
underlying latent variable Y ∗ we assume the mixed-effects regression model
Y ∗i = α0 + α1Gi + σGY b
Y
i + σǫ
Y
i ,
where ǫYi ∼ Nni(0, Ini) is independent of bYi . Here α = (α0, α1) denotes
the regression coefficient vector with α0 the intercept and α1 the parameter
representing the effect of the genotype on Y . At the family level we assume
bYi ∼ Nni(0,Ri), with Ri the coefficient of relationships matrix with ele-
ments rlm = 2
−dlm with dlm denoting the genetic distance between subjects
l and m in the family. The parameter σGY represents the residual additive
genetic variation not explained by gij . Note that σGY models the polygenic
inheritance in a family. For identifiability reasons restrictions are required on
both the scale and location of Y ∗, namely we set σ2 = 1 and γ1 = 0. Thus, in
the mixed-effects probit regression the disease risk πij = P (yij = 1 | bYij, gij)
conditional on the random-effects bYij and genotypic information gij is mod-
elled as follows
P
(
Yij = 1 | gij , bYij
)
= Φ
(
α0 + α1gij + σGY b
Y
ij
)
, (3)
with Φ (z) the cumulative distribution function of the standard normal dis-
tribution. The marginal density under the probit model takes the form:
f(yij | gij ;α, σb) =
∫
bYi
∫ γyij+1
γyij
f(y∗ij | gij , bYi ;α, σb)f(bYi )dy∗ijdbYi .
To model the secondary phenotype Xi we use a linear mixed model:
Xi = β0 + β1Gi + σGX b
X
i + σǫǫ
X
i , (4)
where β = (β0, β1) denotes the regression coefficient vector with β0 the
intercept and β1 the parameter representing the effect of the genotype on X,
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bXi is the random parameter used to model the genetic correlation structure
within each family for the secondary trait, and σǫ is the residual standard
deviation.
To model jointly X and Y using the model specifications (3 and 4), we
introduce a shared random effect uij ∼ N(0, 1) and propose the following
model:
Y ∗i = α0 + α1Gi + σGY b
Y
i + σuui + ǫ
Y
i ,
Xi = β0 + β1Gi + σGX b
X
i + δσuui + σǫǫ
X
i ,
(5)
where ui is assumed to be independent of b
Y
i , b
X
i , ǫ
Y
i , and ǫ
X
i . We in-
troduce a coefficient δ in order to have different phenotypic variances for
the random effect ui. In case of small datasets or small family sizes, it
can be better to constrain δ to be equal to 1 for a simpler model. Let
ΣXi and ΣY ∗i denote the corresponding variance-covariance matrices of the
marginal distributions of Xi and Y
∗
i and let ΣXY ∗i be their covariance.
The joint distribution of the primary and the secondary phenotype is then
(Y ∗i ,Xi) ∽ N2ni
([
α0 + α1Gi
β0 + β1Gi
]
,
[
ΣY ∗i ΣXY ∗i
ΣXY ∗i ΣXi
])
. In the special case
for ni = 2, the variance-covariance matrix becomes:
Σi =


σ2GY + σ
2
u + 1 σ
2
GY
2−d(1,2) σGXσGY + δσ
2
u σGXσGY 2
−d(1,2)
σ2GY 2
−d(1,2) σGY + σ
2
u + 1 σGXσGY 2
−d(1,2) σGXσGY + δσ
2
u
σGXσGY + δσ
2
u σGXσGY 2
−d(1,2) σ2GX + δ
2σ2u + σ
2
ǫ σ
2
GX
2−d(1,2)
σGXσGY 2
−d(1,2) σGXσGY + δσ
2
u σ
2
GX
2−d(1,2) σ2GX + δ
2σ2u + σ
2
ǫ

 .
(6)
Using the properties of the multivariate normal distribution, the joint distri-
bution for the observed primary and secondary phenotypes takes the form:
P (Yi,Xi | Gi) =
∫
P (Y ∗i ,Xi | Gi) dy∗i
=
∫
P (Y ∗i | Xi, Gi)P (Xi | Gi) dy∗i
= P (Xi | Gi)
∫
P (Y ∗i | Xi, Gi) dy∗i .
Thus by using the probit regression model for the primary trait we have de-
veloped an efficient approach to model the correlation between the primary
and secondary trait.
From model (5) and the variance-covariance matrix (6), several marginal
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correlations between and within family members can be deduced:
cor
(
Xij ,Xij′
)
=
σ2GX2
−d(j,j′)(
σ2GX + δ
2σ2u + σ
2
ǫ
) = ρX
cor
(
Y ∗ij, Y
∗
ij′
)
=
2−d(j,j
′)σ2GY(
σ2GY + σ
2
u + 1
) = ρY
cor
(
Xij , Y
∗
ij
)
=
σGXσGY + δσ
2
u√(
σ2GX + δ
2σ2u + σ
2
ǫ
)(
σ2GY + σ
2
u + 1
) = ρXY
cor
(
Xij, Y
∗
ij′
)
=
2−d(j,j
′)σGXσGY√(
σ2GX + δ
2σ2u + σ
2
ǫ
)(
σ2GY + σ
2
u + 1
) = ρ′XY ,
where ρXY represents the association between the primary and secondary
phenotype. We can also derive the closed form for the heritability estimates
of the secondary phenotype which quantifies the percentage of genetic vari-
ation in the total variance:
H2 =
σ2GX(
σ2GX + δσ
2
u + σ
2
ǫ
) . (7)
Note that when genetic factors are included in the model formula (7) gives
the residual heritability.
2.3 Genotype probability
Finally another key component in the formulation of the retrospective like-
lihood (2) is the computation of the genotype probability for each family
i. Let Gmj and Gpj denote the genotypes of the mother and father of an
individual j if this individual is a nonfounder member of family i. Under
the assumption of random mating and mendelian inheritance, the genotype
probabilities can be written as presented by Duncan Thoms[14]:
P (Gi) =
J∏
j=1
{
P (gij | Gmj , Gpj) if j is a nonfounder
P (gij) if j is a founder
.
The probabilities P (gij | Gpj, Gmj) are the transmission probabilities which
can be modelled using mendelian inheritance. Finally P (Gpi), P (Gmi), and
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P (gij) can be modelled by assuming Hardy-Weinberg proportions (1− q)2,
2q (1− q), q2 which depend on q, the minor allele frequency. Here we propose
to use external information for q or to estimate q from the control sample
before maximizing the likelihood. Note that when genotypes of the parents
are missing the probability can be obtained by summing over the possible
parental genotypes. In case of more complex pedigree a recursive algorithm
known as peeling (Elston and Stewart, 1971) can be used [15]. For the LLS
where families are sibships the probability is as follows:
L (θ;Y,X) =
∏
i
{
P (Xi | Gi)
∫
P (Y ∗i | Xi, Gi) dy∗i
}∑
Gp
∑
Gm
∏
j P (Gij | Gm, Gp)P (Gp)P (Gm)∑
g
∑
Gp
∑
Gm
∫
P (Y ∗i | g)P (g | Gm, Gp)P (Gp)P (Gm)
,
(8)
where θ = (α0, α1, σGY , β0, β1, σGX , σǫ, δ, σu) is the model parameters vector.
2.4 Estimation and statistical testing
To estimate the parameters of the joint model we maximize the logarithm
of the likelihood described in (2). This involves a combination of numerical
optimization and integration. For the evaluation of the integral in the mul-
tivariate normal distribution, we use the deterministic algorithm Miwa de-
scribed in [16]. For the optimization, we use the Broyden-Fletcher-Goldfarb-
Shanno (BFGS) algorithm implemented in the function optim(.) in R. The
BFGS algorithm is a quasi-Newton method, which means that the Hessian
matrix does not need to be evaluated directly but is approximated by using
specified gradient evaluations. To test for the presence of an effect of the
SNPs on the secondary phenotype we use the likelihood ratio test. Note
that when the interest of a researcher is solely testing for genetic association
a score statistic can might be an alternative for the likelihood ratio statistic.
2.5 Continuous polygenic score
Our approach can also be applied in the case of modelling the associa-
tion between continuous covariates and secondary phenotypes. For example
polygenic scores have been used to summarise genetic effects among an en-
semble of SNPs that have been identified in large GWASes [17, 18, 19]. Poly-
genic scores are typically linear combinations of SNPs: G =
∑
k δkSNPk,
where δk = 1 or δk is obtained from previous GWASes. For genetic scores,
we need to integrate over the distribution of the polygenic score instead
of summing over the genotypes in the denominator of (2). For the dis-
tribution of the polygenic score we use a multivariate normal distribution
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Gi ∽ Nni (µg, σgRi), with µg the mean value of the genetic score, σg the
standard deviation of the genetic score and Ri the relationship matrix of
family i. The likelihood contribution for family i is given by:
P (Yi,Xi | Gi)P (Gi)
P (Yi)
=
P (Yi,Xi | Gi)P (Gi)∫
y∗i
P (y∗i )dy
∗
i
=
P (Yi,Xi | Gi)P (Gi)∫
y∗
∫
gi
P (y∗i | gi)P (g)dy∗i dgi
.
Computation of the integral
∫
y∗
∫
g
P (y∗ | g)P (g)dy∗dg can be quite intensive
and challenging. In order to gain efficiency we write the marginal model of
Y ∗ (5) as Y ∗i = α0+b
Y ∗
i +ui+ǫ
Y
i , with b
Y ∗
i = σGY b
Y
i +α1Gi. Now Y
∗
i follows
the following multivariate normal distribution: Y ∗i ∽ Nni
(
α0 + α1µg,ΣY ∗i + α
2
1σ
2
gRi
)
.
Note that when a polygenic risk score is included in the model for the sec-
ondary phenotype, the parameter σGY represents the residual polygenic in-
heritance.
2.6 Inclusion of covariates in the model
Often, researchers want to adjust for covariates such as age, sex, treatment
etc in the model. Let Z be such a covariate. To estimate the effect Z on
the secondary phenotype we propose to maximize the joint likelihood of X
and G conditionally on the primary phenotype Y and Z. Thereby we avoid
modeling of the distribution of Z within the families. Indeed, under the
assumption of independence between genotype and Z we obtain:
P (Xi, Gi | Yi, Zi) = P (Xi, Yi, Zi, Gi)
P (Yi, Zi)
=
P (Xi, Yi | Gi, Zi)P (Gi)P (Zi)
P (Yi|Zi)P (Zi) =
P (Xi, Yi | Gi, Zi)P (Gi)
P (Yi|Zi) .
(9)
3 Simulation Study
A simulation study has been set up to evaluate the performance of our
proposed method for the estimation of the association between a genetic
factor and the secondary phenotype and the estimation of the heritability of
the secondary phenotype. We compare our method with the naive approach
which is typically followed in practice, namely analysis of the secondary trait
without correcting for the sampling mechanism. In particular, in this case,
we fit the standard linear mixed-effects model for the secondary phenotype
and explicitly model the familial relationships as described in (4). The two
methods are compared in terms of bias, Root Mean Square Error (RMSE)
and 95% coverage probabilities. We consider SNPs (discrete variables) and
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polygenic scores (continuous variables). Several settings are considered for
the disease prevalence, the strength of the association between the genetic
factor and the primary phenotype, the strength of the ascertainment mech-
anism and the number of families. We use families of size 5. With respect to
the familial relationships, we consider only sibships such that our simulation
resembles the LLS design. For the prevalence of the primary phenotype we
consider two settings namely a disease prevalence of 1% which corresponds
to α0 ≈ −2.32 and of 5% which corresponds to α0 ≈ −1.64. In addition the
variance parameters have been chosen such that they correspond to a her-
itability of 50%. Specifically we use σGX=2, σGY =
√
3, σuX = σuY =
√
2
and σǫ =
√
2. This corresponds to a correlation of 0.78 between the primary
and the secondary phenotypes. To speed up computations, we assume that
σuX = σuY when fitting the models to the simulated datasets. For each
scenario, 500 datasets are simulated using model (5).
3.1 Simulation results for a SNP
The genotypes of the SNPs are simulated assuming a minor allele frequency
of 0.3 in the population. For the secondary phenotype model the following
fixed effects values are used: β0 = 3.5 and β1 = 0.2, whereas for the primary
phenotype model the effect sizes are α1 = 0.1 or 0.5. Finally, for each of the
four scenarios (rare or common disease, and weak and strong SNP effect on
the primary phenotype) we consider two ascertainment mechanisms, namely
the sampled families of size five have at least one affected and at least two
affected members.
Figure 2 presents the estimates and 95% confidence intervals for the sce-
nario of 400 families. Figure 2 shows that ignoring the sampling mechanism
(naive method) leads to biased estimates of the SNP effect and the size of
this bias increases with the strength of the ascertainment mechanism and
the association between the SNP and the primary phenotype. Overall we
observe that our method gives unbiased estimates of the SNP effect on the
secondary phenotype. The coverage probabilities reach the nominal level
(see section A of supplementary material). Regarding the prevalence of the
primary phenotype, we observe that for the naive method bias increases with
lower prevalence, while our method remains robust to the lower amount of
information due to the rare primary phenotype. In general, our method leads
to smaller RMSE than the naive approach and better coverage probabilities.
In Table 2 we present the heritability estimates of the secondary phe-
notype for a common disease, under the various ascertainment mechanisms
and the two values of α1. It is obvious that the heritability estimates are in-
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fluenced by the ascertainment mechanisms when using the naive approach.
Indeed the naive method tends to underestimate the heritability for each
mechanism and this underestimation is getting larger as the ascertainment
mechanisms become more stringent. The heritability estimates are 25-27%
for families with at least one affected sibling and drop to 13-14% for families
with at least 2 affected siblings. On the contrary, our method is robust to
the stringency of the ascertainment mechanism.
Next, we investigate the performance of our approach in terms of type I
error in each of the four considered scenarios. We simulate 10,000 replicates
for each scenario. In Table 1 the type I error rates are given for the rare
disease scenario (i.e. prevalence 1%). We observe that while our approach
preserves the type I error rate at a nominal level, the naive approach has,
systematically, an inflated type I error rate. The type I error rate for the
naive method increases with stronger ascertainment and larger SNP effect
on the primary phenotype.
Finally, we study the robustness of our approach to one violation of the
model assumptions, namely we simulated under a logit link for the primary
phenotype and used the probit link for modelling. Results for the SNP
effect and the heritability are presented in Table 3. These results show that
even though our approach gives biased estimates for the primary phenotype
model, the parameters estimates for the secondary phenotype model are not
affected. All the results are presented in Section A of the Supplementary
Material.
3.2 Simulation results for a polygenic score
To study the performance of our method for polygenic score, we simulated
centered and standardized scores. The parameters of the secondary pheno-
type model were chosen as for the SNP simulations: β0 = 3.5 and β1 = 0.2,
whereas for the primary phenotype model effect sizes of α1 = 0.1 or 0.5 were
used. Figure 3 presents the estimates and confidence intervals for datasets
with 400 families. Our approach provides unbiased estimates of the effect
of the polygenic score on the secondary phenotype. In contrast, the naive
approach provides biased estimates and the bias increases when the ascer-
tainment process is more stringent or when α1 is larger.
In Table 2 the simulations results with regard to the heritability es-
timates are given. The results of the residual heritability estimates after
adjustment for polygenic scores agree with the results obtained when a SNP
is included in the model. The naive approach did not perform well: esti-
mates between 25-26% and 14-15% for an ascertainment process of at least
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one affected sibling and at least two affected siblings respectively instead of
50%.
4 Application: Analysis of the Leiden Longevity
Study
In this Section, we will exemplify our proposed method in the analysis of the
LLS which has been briefly introduced in Section 1. The LLS is a family-
based study which has been set up to identify mechanisms that contribute
to healthy ageing and longevity. The inclusion criteria of the study are
families with at least two nonagenarian siblings, i.e. the selection takes
place at Generation II (Figure 4). Several secondary phenotypes and GWAS
data have been measured for the offspring of these siblings (Generation
III in Figure 4) and their partners. Since the offspring have at least one
nonagenarian parent, they are also likely to become long-lived. Therefore,
the set of offspring and their partners corresponds to a case-control design
with related subjects where the offspring in Generation III are considered as
cases and their partners as controls. Overall 421 families with 1671 offspring
(cases) and 744 partners (controls) have been included in the study. Because
the families are relatively small we use the model which assumes an equal
variance for the shared effect for the two traits.
Here we model the association between genetic factors and the secondary
phenotypes triglyceride and glucose levels. For both traits, there is evidence
of an association with human longevity and both traits are normally dis-
tributed. For the sake of comparison in addition to our proposed method,
we will present results using the naive approach i.e. standard linear mixed
model. Analyses using the linear mixed model which conditions also on the
case-control status will not be presented because the parameters do not have
a comparable interpretation between the two approaches.
4.1 Triglyceride levels analysis
Triglyceride levels have been found to be associated with the primary trait
longevity (p-value = 0.0005 for women and p-value = 0.04 for men) and the
size of association is sex dependent. Therefore a sex-stratified analysis has
been considered further. For the purposes of our illustration, we restricted
our analysis to seven genes on chromosome 11 which are known to be asso-
ciated with Triglyceride levels. These genes are APOA1, APOA4, APOA5,
APOC3, ZNF259, BUD13 and DSCAML1. For these genes, we have geno-
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types of 41 SNPs which have no missing values in our datasets. Triglyceride
levels were standardized and we included age as a covariate in the analysis.
We ran the analysis with the constrained approach, i.e. δ = 1. We ob-
serve that none of the SNPs analysed is significantly associated with Triglyc-
eride levels neither in men nor in women, hence for most SNPs the estimates
of the effect sizes agree between the two approaches. The SNPs showing the
largest differences are, in men, SNP 22: βRA1 = 0.047 for our Retrospective
Approach (RA) and βNA1 = 0.052 for the Naive Approach (NA) and SNP
26: βRA1 = 0.088 and β
NA
1 = 0.092. For women more SNPs give different
estimates between the two approaches, i.e. SNP 1 (βRA1 = 0.024, β
NA
1 =
0.020), SNP 2 (βRA1 = 7.2e-06 β
NA
1 =0.006), SNP 13 (β
RA
1 = -0.013, β
NA
1 =
-0.009) and SNP 19 (βRA1 = 0.011, β
NA
1 = 0.007) showed the biggest differ-
ences. Results for the SNPs are presented in Section B of the Supplementary
Material.
We verified whether the assumption of equal variances for the primary
and secondary phenotype for the shared effects is justified. We fitted also
the model with non constrained δ. We noticed that for some of the SNPs the
model parameters are hard to estimate and a switch between the estimates
of the variances of the shared and residual random effects in the model for
the second phenotype seems to occur. Overall the estimates of the effect of
the SNP on the secondary phenotype are very similar to the model which
assumes equal variances. Results of these analyses are presented in Section
B of the Supplementary Material.
4.2 Glucose levels analysis
We now proceed with the analysis of glucose levels in the offspring and part-
ners of the LLS. Mooijart [20] studied the association between glucose and
a polygenic score. The genetic score was defined as the total number of risk
alleles across 15 SNPs which are known to be associated with Type II di-
abetes. The Generalized Estimating Equation method was applied to take
into account the familial relationships. The paper showed that a higher
number of Type II diabetes risk alleles is associated with a higher serum
concentration of glucose (p − value = 0.016). A statistically significant as-
sociation was found between glucose level and case-control status (p-value<
0.001). However, the sampling process was not taken into account in the
analysis and thus the results might be biased. We applied our method to
estimate the heritability of glucose levels and to test for the presence of an
association between the glucose levels and the polygenic score. In addition,
we applied the naive approach which did not correct for case-control status.
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We did not stratify according to sex in these analyses.
For this analysis the polygenic score was standardized. Using the Retro-
spective approach, the association between the genetic score and the glucose
level is estimated by βRA1 = 0.630 with a standard error of stE = 0.023
(p − value = 0.015). The naive approach also yields a significant asso-
ciation between the genetic score and glucose levels but with a different
β (βNA1 = 0.622, stE = 0.026, p − value = 0.020). By using the Naive
Approach (NA) we obtained for the glucose levels a genetic variance of
σ2GX = 0.302 and a total variance of σ
2
T = 1.322, which corresponds to
a residual heritability of h2NA = 0.228. Our Retrospective approach (RA)
yields a genetic variance of σ2GX = 0.384 and a total variance of σ
2
T = 1.457
which corresponds to a residual heritability of h2RA = 0.263.
5 Discussion
In this paper, we developed a new method for the proper analysis of sec-
ondary traits for multiple-cases family designs. A key component in our
proposed method is the joint modelling of the primary and secondary phe-
notypes. We developed a multivariate probit model which can also capture
the within families dependencies. A retrospective likelihood approach has
been followed to correct for the ascertainment process. Thereby unbiased
estimates of the association between genetic factors and secondary traits
can be obtained. Simulation results showed that our approach preserves the
type I error at nominal level and provides accurate estimates irrespective of
the disease prevalence, the strength of the association between the genetic
variants and the primary phenotype, and the ascertainment mechanism. An-
other important empirical finding is that the heritability estimates for the
secondary traits can be severely underestimated unless the sampling mech-
anism is taken into account. With respect to the analysis of the motivating
case study, for the SNPs the differences between the effect sizes obtained by
our proposed method and the naive approach were small. However typically
many SNPs are considered and small differences might, therefore, be im-
portant. With regard to the effect size of the genetic score and the residual
heritability of glucose, the difference between our approach and the naive
approach was larger.
Heritability is one of the properties that a trait needs to possess to be
declared an endophenotype for a specific disease. The other criteria are: the
trait is associated with the disease status in the population, the trait is pri-
marily state-independent, and the trait and the disease status co-segregate
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within a family [21]. The Leiden Family Lab (https://www.leidenfamilylab.nl)
aims to identify endophenotypes for social anxiety disorder. The study com-
prises families with at least two cases with social anxiety. The methods
presented in this paper will be used for the analyses of this study to identify
endophenotypes and are relevant for other family studies, as well.
In this paper, we proposed to include additional covariates in the model
by using the likelihood conditional on these covariates. Alternatively the
joint likelihood of the secondary phenotype, genotype, and covariate condi-
tionally on the primary phenotype can be used. This alternative approach
might be more efficient [22]. However this likelihood requires distributional
assumptions for the covariates within families which can be complex for re-
lated individuals. Moreover maximization of the likelihood might become
time consuming. Ghosh et al [23] propose a pseudo-likelihood and a profile
approach to include covariates in a secondary phenotype analysis for case-
control data. This work needs to be extended to family data. A Monte
Carlo approach might be considered to compute the integrals (Tsonaka et
al [24]). This is a topic for future research.
Typically there are missing genotypes. In unrelated individuals, geno-
types can be imputed based on the haplotype structure obtained from a
reference panel. For family data, the imputation should also take into ac-
count the genotypes of other family members. Software exists which can
perform such analysis, for example the Genotype Imputation Given Inheri-
tance (GIGI) program [25]. However for the computation of the denominator
in equation (2) these imputed genotype probabilities have to be taken into
account. How to incorporate them is a topic for future research.
Due to the computational intensity of the proposed method, it is not yet
possible to run full GWAs analyses of secondary phenotypes. However, our
method can be used on a set of pre-selected variants e.g. after an initial
screening with the naive approach to the primary and secondary pheno-
types or when investigating pleiotropic effects. For fastest computation of
the multivariate integrals in the numerator and the denominator, a faster
algorithm can be used than the one used in this paper. The randomized
Quasi-Monte-Carlo procedure, developed by Genz [26], is less accurate but
faster especially for large pedigrees. Development of less computational in-
tensive methods is one of the topics for future research.
With regard to pleiotropic effects, a criticism of probit random-effects
models is that in the presence of high dimensional random effects we cannot
move from the subject-specific interpretation for the fixed effects parameters
to the population-level interpretation as in the random-intercepts case. Note
that when the binary outcome of interest and when we have relatively small
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family studies, the intercept and variance terms might be hard to estimate
due to lack of information and poor coverage probabilities are observed.
Tsonaka et al [5] showed that by using information on the prevalence of
the disease efficiency can be gained. Their methods need to be adapted to
our setting of the analysis of two phenotypes. When the parameters of the
primary phenotype model are not of interest and this model is only used
to correct for the ascertainment mechanism which is driven by the primary
phenotype, we showed that secondary phenotype analyses with our method
are robust to using the probit instead of the logit link function.
Several other extensions and future directions can be followed. First,
in the LLS and the Leiden Family Lab Study several omics and fMRI data
will become available in the near future, respectively, and joint modelling
of several glycans or voxels is of interest. Extending our approach, in this
case, is algebraically straightforward, but it might be hard to implement in
practice due to its computational intensity especially with a high number of
secondary phenotypes. Use of composite likelihood approaches might be a
solution and is one of our future research topics.
Finally, an attractive alternative approach to properly analyse secondary
traits is to apply inverse probability weighting. However, it is crucial to cor-
rectly specify the weights. Currently, we do not have sufficient information
to be able to estimate these weights for our studies. However with the
availability of electronic health records, such as information from general
practitioners, for research, we might have access to the information needed
to estimate the weights and inverse probability weighting approaches can be
developed.
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Table 1: Type I errors rates for testing for association between a genetic
marker and a secondary phenotype for four scenarios. Families with at
least one and with at least two cases are considered. Two values for the
association between the SNP and the primary phenotype namely α1 = 0.1
and α1 = 0.5 are used. Datasets consist of 400 families of size 5. Results
are based on 10000 replicates.
nominal level (α) Retrospective likelihood Naive method
At least 2 cases
α1 =0.1
0.05 0.0509 0.0580
0.01 0.0118 0.0152
0.001 0.0017 0.0025
α1 =0.5
0.05 0.0505 0.0878
0.01 0.0113 0.0222
0.001 0.0013 0.0043
At least 1 case
α1 =0.1
0.05 0.0524 0.0514
0.01 0.0102 0.0098
0.001 0.0018 0.0014
α1 =0.5
0.05 0.0522 0.0558
0.01 0.0098 0.0097
0.001 0.0009 0.0016
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Table 2: Heritability results of the simulation studies for a SNP and a poly-
genic score: Estimates with standard deviations and RMSE (in brackets) for
the heritability of the secondary phenotype for a common disease (preva-
lence ≈ 5%), when families with at least one and at least two cases are
sampled and for two values of α1, i.e. SNP or polygenic score effect on
primary phenotype. Datasets consist of 400 families of size 5. Results are
based on 500 replicates.
SNP model Polygenic score model
Ascertainment α1 Retrospective Naive Retrospective Naive
1. 2 cases
0.10 0.48(0.07)(0.22) 0.13(0.07)(0.37) 0.50(0.03)(0.13) 0.14(0.03)(0.36)
0.50 0.48(0.07)(0.22) 0.14(0.07)(0.36) 0.52(0.03)0.12) 0.15(0.03)(0.34)
2. 1 case
0.10 0.50(0.08)(0.17) 0.25(0.08)(0.25) 0.48(0.04)(0.12) 0.25(0.03)(0.24)
0.50 0.50(0.08)(0.17) 0.27(0.08)(0.24) 0.50(0.04)(0.10) 0.26(0.04)(0.23)
Table 3: Robustness: Estimates of the effect size of the SNP on the sec-
ondary phenotype (β1) and heritability of the secondary phenotype are given
for a common disease (prevalence ≈ 5%), for the two ascertainment mech-
anisms and two values of α1. Into brackets are standard deviations, RMSE
and coverage probability (for the effect size only). Datasets consist of 400
families of size 5. Results are based on 500 replicates.
Ascertainment α1 β1 heritability
0.True value 0.200 0.500
1.At least 2 cases
0.100 0.199(0.104)(0.104)(0.948) 0.509(0.017)(0.110)
0.500 0.197(0.106)(0.110)(0.945) 0.516(0.014)(0.108)
2.At least 1 case
0.100 0.200(0.104)(0.107)(0.961) 0.510(0.012)(0.096)
0.500 0.199(0.107)(0.111)(0.960) 0.513(0.010)(0.087)
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Figure 1: Directed acyclic graph representing the case where bias is ex-
pected when estimating the association between the genetic marker and the
secondary phenotype. Arrows represent existing association between each
node of the graph. A secondary phenotype analysis investigates whether
there is an association between the genetic factor and the secondary pheno-
type
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Figure 2: Estimates and 95% confidence intervals for the SNP effect on the
secondary phenotype for the retrospective likelihood approach and the naive
method. Results are obtained from 500 simulated datasets of 400 families
for 2 ascertainment schedules. The top and bottom panel correspond to a
rare or common primary phenotype with a prevalence around 1% and 5%
respectively. In black and red are represented results for small (α1=0.1)
and large (α1=0.5) effect sizes of the SNP on the primary phenotype, re-
spectively. The horizontal line corresponds to the true SNP effect on the
secondary phenotype.
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Figure 3: Estimates and 95% confidence intervals for the polygenic score
effect on the secondary phenotype for the retrospective likelihood approach
and the naive method. Results are obtained from 500 simulated datasets of
400 families for 2 ascertainment schedules. The top and bottom panel cor-
respond to a rare or common primary phenotype with a prevalence around
1% and 5% respectively. In black and red are represented results for small
(α1=0.1) and large (α1=0.5) effect sizes of the polygenic score on the pri-
mary phenotype, respectively. The horizontal line corresponds to the true
polygenic score effect on the secondary phenotype.
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Figure 4: Example of a family pedigree from the LLS. Squares and circles
represent men and women respectively, crossed symbols represent deceased
individuals. In black are the long-lived individuals on whom the ascertain-
ment is based, in grey are the cases of the study (offsprings of long-lived
siblings) and in white are the controls.
25
6 Supplementary Material for: Secondary pheno-
type analysis in ascertained family designs: Ap-
plication to the Leiden Longevity Study
In this supplementary materials, we are presenting all the simulations re-
sults obtained to compare our restrospective likelihood approach to the naive
mixed model approach in Section A. In section B are presented the associ-
ation results between 41 selected SNPs and triglyceride levels obtained on
the Leiden Longevity Study.
6.1 Simulation results
6.1.1 Description of the simulation study
A simulation study has been set up to evaluate the performance of our pro-
posed method in various settings for the correlation between the two out-
comes, the disease prevalence, the strength of the association between the
SNP and the primary phenotype and strength of the ascertainment mecha-
nism. In addition, we contrasted our method with the naive approach which
is typically followed in practice, namely analysis of the secondary trait with-
out correcting for the sampling mechanism. In particular in this case we
applied the standard linear mixed effects model for the secondary pheno-
type and explicitly modelled the familial relationship. The two methods
have been compared in terms of Root Mean Square Error (RMSE), and
95% coverage probabilities. We simulate multiple cases family data and sec-
ondary phenotypes for sibships using the mixed-effects logistic regression:
Y ∗i = α0 + α1Gi + σGY b
Y
i + σuui + ǫY i
Xi = β0 + β1Gi + σGX b
X
i + σuui + σǫǫXi
(10)
With respect to the familial relationships we have simulated families with
only siblings such that our simulation resembles more the LLS design. For
the prevalence of the primary phenotype we considered two cases: the disease
prevalence equals 1% which corresponds to α0 ≈ −2.32 and 5% which corre-
sponds to α0 ≈ −1.64. The SNP effect on the primary phenotype measured
by α1, was taken equal to 0.1, 0.5 or 1. In addition the remaining variance
parameters have been chosen such that they correspond to 50% heritability,
i.e. ,σGX=2, σGY =
√
3, σu =
√
2 and σǫ =
√
2. which corresponds to 0.78
correlation between the primary and the secondary phenotypes. Finally for
the secondary phenotype we choose as fixed effects values :β0 = 3.5 and
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β1 = 0.2 or 2. Finally for each of the 4 scenarios (rare or low disease and
low and higher SNP effect on the primary phenotype) we considered 4 as-
certainment mechanisms, i.e. we assumed that families have been sampled
provided that at least 1 or 2 out of the 5 members are affected. For each
dataset 400 families were simulated.
6.1.2 Simulation study results for a SNP as genetic marker
Table S1: Simulations results obtained on 500 datasets with 400 families
of size 5 with at least 2 cases of a rare disease (prevalence around 1%)
and α1=0.1. Into brackets are respectively standard deviations, root mean
square errors and the coverage probabilities.
Real Value Retrospective likelihood Naive method
Est (SD) (RMSE) (Cov Pr) Est (SD) (RMSE) (Cov Pr)
β0 3.500 3.612(1.444)(1.533)(0.859) 5.192(0.178)(1.702)(0.000)
β1 0.200 0.211(0.204)(0.212)(0.936) 0.195(0.215)(218)(0.934)
σGX 2.000 1.841(0.479)(0.795)(0.622) 0.913(0.583)(1.131)(0.128)
σǫ 1.414 1.552(0.145)(0.271)(0.662) 2.471(0.049)(1.063)(0.000)
α0 -2.326 -2.279(1.650)(2.112)(0.773) -
α1 0.100 0.087(0.176)(0.196)(0.906) -
σGY 1.732 1.317(0.677)(0.965)(0.844) -
σu 1.414 0.995(0.687)(0.778)(0.730) -
Table S2: Simulations results obtained on 500 datasets with 400 families
of size 5 with at least 2 cases of a rare disease (prevalence around 1%)
and α1=0.5. Into brackets are respectively standard deviations, root mean
square errors and the coverage probabilities.
Real Value Retrospective likelihood Naive method
Est (SD) (RMSE) (Cov Pr) Est (SD) (RMSE) (Cov Pr)
β0 3.500 3.678(1.140)(1.172)(0.932) 5.099(0.185)(1.610)(0.000)
β1 0.200 0.191(0.212)(0.228)(0.906) 0.108(0.198)(0.234)(0.893)
σGX 2.000 1.899(0.561)(0.693)(0.728) 0.974(0.458)(1.068)(0.106)
σǫ 1.414 1.529(0.123)(0.231)(0.707) 2.444(0.051)(1.038)(0.000)
α0 -2.326 -1.989(1.449)(1.814)(0.793) -
α1 0.500 0.416(0.173)(0.262)(0.905) -
σGY 1.732 1.461(0.673)(1.044)(0.876) -
σu 1.414 1.072(0.671)(0.730)(0.813) -
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Table S3: Simulations results obtained on 500 datasets with 400 families
of size 5 with at least 1 case of a rare disease (prevalence around 1%)
and α1=0.1. Into brackets are respectively standard deviations, root mean
square errors and the coverage probabilities.
Real Value Retrospective likelihood Naive method
Est (SD) (RMSE) (Cov Pr) Est (SD) (RMSE) (Cov Pr)
β0 3.500 3.439(1.190)(1.216)(0.912) 4.361(0.194)(0.883)(0.002)
β1 0.200 0.200(0.209)(0.213)(0.955) 0.192(0.214)(0.216)(0.950)
σGX 2.000 1.983(0.257)(0.278)(0.679) 1.363(0.195)(0.683)(0.054)
σǫ 1.414 1.552(0.119)(0.234)(0.644) 2.356(0.058)(0.951)(0.000)
α0 -2.326 -2.470(1.951)(2.169)(0.902) -
α1 0.100 0.074(0.174)(0.191)(0.932) -
σGY 1.732 1.553(0.574)(0.973)(0.765) -
σu 1.414 0.973(0.677)(0.745)(0.862) -
Table S4: Simulations results obtained on 500 datasets with 400 families
of size 5 with at least 1 case of a rare disease (prevalence around 1%)
and α1=0.5. Into brackets are respectively standard deviations, root mean
square errors and the coverage probabilities.
Real Value Retrospective likelihood Naive method
Est (SD) (RMSE) (Cov Pr) Est (SD) (RMSE) (Cov Pr)
β0 3.500 3.377(0.940)(0.927)(0.949) 4.293(0.199)(0.816)(0.008)
β1 0.200 0.195(0.218)(0.218)(0.943) 0.155(0.202)(0.218)(0.920)
σGX 2.000 1.995(0.233)(0.233)(0.704) 1.409(0.188)(0.641)(0.092)
σǫ 1.414 1.544(0.115)(0.213)(0.674) 2.329(0.059)(0.924)(0.000)
α0 -2.326 -2.342(1.530)(1.536)(0.961) -
α1 0.500 0.412(0.156)(0.283)(0.877) -
σGY 1.732 1.578(0.556)(0.983)(0.787) -
σu 1.414 1.027(0.597)(0.698)(0.888) -
Table S5: Simulations results obtained on 500 datasets with 400 families of
size 5 with at least 2 cases of a common disease (prevalence around 5%)
and α1=0.1. Into brackets are respectively standard deviations, root mean
square errors and the coverage probabilities.
Real Value Retrospective likelihood Naive method
Est (SD) (RMSE) (Cov Pr) Est (SD) (RMSE) (Cov Pr)
β0 3.500 3.397(1.463)(1.530)(0.901) 4.835(0.180)(1.356)(0.000)
β1 0.200 0.202(0.204)(0.205)(0.939) 0.188(0.203)(0.207)(0.940)
σGX 2.000 1.919(0.467)(0.653)(0.650) 1.053(0.362)(0.990)(0.060)
σǫ 1.414 1.543(0.131)(0.238)(0.699) 2.404(0.052)(0.998)(0.000)
α0 -1.644 -1.755(1.801)(2.091)(0.874) -
α1 0.100 0.075(0.169)(0.222)(0.902) -
σGY 1.732 1.470(0.669)(1.035)(0.837) -
σu 1.414 0.991(0.730)(0.765)(0.798) -
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Table S6: Simulations results obtained on 500 datasets with 400 families of
size 5 with at least 2 cases of a common disease (prevalence around 5%)
and α1=0.5. Into brackets are respectively standard deviations, root mean
square errors and the coverage probabilities.
Real Value Retrospective likelihood Naive method
Est (SD) (RMSE) (Cov Pr) Est (SD) (RMSE) (Cov Pr)
β0 3.500 3.393(1.179)(1.156)(0.952) 4.753(0.187)(0.1.266)(0.000)
β1 0.200 0.197(0.212)(0.215)(0.946) 0.103(0.201)(0.221)(0.930)
σGX 2.000 2.003(0.327)(0.513)(0.700) 1.131(0.299)(0.912)(0.032)
σǫ 1.414 1.523(0.114)(0.193)(0.702) 2.376(0.053)(0.970)(0.000)
α0 -1.644 -1.623(1.432)(1.663)(0.952) -
α1 0.500 0.409(0.170)(0.276)(0.926) -
σGY 1.732 1.530(0.570)(0.967)(0.864) -
σu 1.414 1.033(0.725)(0.763)(0.878) -
Table S7: Simulations results obtained on 500 datasets with 400 families
of size 5 with at least 1 case of a common disease (prevalence around 5%)
and α1=0.1. Into brackets are respectively standard deviations, root mean
square errors and the coverage probabilities.
Real Value Retrospective likelihood Naive method
Est (SD) (RMSE) (Cov Pr) Est (SD) (RMSE) (Cov Pr)
β0 3.500 3.285(1.203)(1.288)(0.904) 4.124(0.198)(0.653)(0.110)
β1 0.200 0.203(0.209)(0.209)(0.946) 0.191(0.205)(0.217)(0.940)
σGX 2.000 1.999(0.237)(0.479)(0.660) 1.471(0.172)(0.586)(0.134)
σǫ 1.414 1.559(0.116)(0.221)(0.672) 2.291(0.061)(0.887)(0.000)
α0 -1.644 -1.991(1.870)(2.450)(0.920) -
α1 0.100 0.085(0.173)(0.221)(0.916) -
σGY 1.732 1.623(0.573)(1.033)(0.742) -
σu 1.414 0.960(0.738)(0.761)(0.894) -
Table S8: Simulations results obtained on 500 datasets with 400 families
of size 5 with at least 1 case of a common disease (prevalence around 5%)
and α1=0.5. Into brackets are respectively standard deviations, root mean
square errors and the coverage probabilities.
Real Value Retrospective likelihood Naive method
Est (SD) (RMSE) (Cov Pr) Est (SD) (RMSE) (Cov Pr)
β0 3.500 3.156(0.939)(0.973)(0.946) 4.066(0.201)(0.599)(0.200)
β1 0.200 0.194(0.222)(0.226)(0.944) 0.158(0.204)(0.234)(0.920)
σGX 2.000 2.035(0.245)(0.254)(0.712) 1.520(0.163)(0.540)(0.176)
σǫ 1.414 1.543(0.124)(0.219)(0.654) 2.263(0.063)(0.861)(0.000)
α0 -1.644 -1.982(1.518)(1.612)(0.960) -
α1 0.500 0.430(0.304)(0.574)(0.898) -
σGY 1.732 1.680(0.574)(1.090)(0.772) -
σu 1.414 0.986(0.666)(0.718)(0.894) -
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Table S9: Estimates with standard deviations and RMSE of the heritability
of the secondary phenotype are given for a common disease (prevalence ≈
5%), for the four ascertainment mechanisms and two values of α1.
Ascertainment α1 Retrospective likelihood Naive method
1.At least 2 cases
0.10 0.49(0.08)(0.21) 0.17(0.08)(0.34)
0.50 0.50(0.08)(0.18) 0.19(0.08)(0.32)
2.At least 1 case
0.10 0.50(0.08)(0.17) 0.29(0.08)(0.22)
0.50 0.52(0.08)(0.16) 0.31(0.08)(0.20)
Table S10: Estimates with standard deviations and RMSE of the heritability
of the secondary phenotype are given for a rare disease (prevalence ≈ 1%),
for the four ascertainment mechanisms and two values of α1.
Ascertainment α1 Retrospective likelihood Naive method
1.At least 2 cases
0.10 0.48(0.07)(0.22) 0.13(0.07)(0.37)
0.50 0.48(0.07)(0.22) 0.14(0.07)(0.36)
2.At least 1 case
0.10 0.50(0.08)(0.17) 0.25(0.08)(0.25)
0.50 0.50(0.08)(0.17) 0.27(0.08)(0.24)
30
−
0.
5
0.
0
0.
5
1.
0
Estimates of SNP effect on secondary phenotype with confidence intervals
minimum number of cases in family
SN
P 
ef
fe
ct
1 2
rare disease, family size =5, 400 families
Retrospective likelihood α1=0.1 
Naive method α1=0.1 
Retrospective likelihood α1=0.5 
Naive method α1=0.5 
−
0.
5
0.
0
0.
5
1.
0
minimum number of cases in family
SN
P 
ef
fe
ct
1 2
common disease, family size =5, 400 families
Retrospective likelihood α1=0.1 
Naive method α1=0.1 
Retrospective likelihood α1=0.5 
Naive method α1=0.5 
Figure S1: Estimates and 95% confidence intervals for the SNP effect on the
secondary phenotype for the retrospective likelihood approach and the naive
method. Results are obtained from 500 simulated datasets of 100 families
for 2 ascertainment schedules. The top and bottom panel correspond to a
rare or common primary phenotype with a prevalence around 1% and 5%
respectively. In black and red are represented results for small (α1=0.5) and
large (α1=1) effect sizes of the SNP on the primary phenotype respectively.
The horizontal line corresponds to the true SNP effect on the secondary
phenotype.
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Table S11: Type I errors rates for testing for association between a marker
and a secondary phenotype for four scenarios. Two ascertainment processes,
namely at least one and at least two cases are considered. Two values for the
association between the SNP and the primary phenotype are used, namely
α1 = 0.1 and α1 = 0.5. We simulated for each scenario 10000 datasets.
nominal level (α) Retrospective likelihood Naive method
At least 2 cases
α1 =0.1
0.05 0.0509 0.0580
0.01 0.0118 0.0152
0.001 0.0017 0.0025
α1 =0.5
0.05 0.0505 0.0878
0.01 0.0113 0.0222
0.001 0.0013 0.0043
At least 1 case
α1 =0.1
0.05 0.0524 0.0514
0.01 0.0102 0.0098
0.001 0.0018 0.0014
α1 =0.5
0.05 0.0522 0.0558
0.01 0.0098 0.0097
0.001 0.0009 0.0016
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Table S12: Simulations results obtained on 500 datasets with 400 families
of size 5 with at least 2 cases of a rare disease (prevalence around 1%)
and α1=0.1. Into brackets are respectively standard deviations, root mean
square errors and the coverage probabilities.
Real Value Retrospective likelihood
Est (SD) (RMSE) (Cov Pr)
β0 3.500 3.586(0.897)(0.910)(0.905)
β1 0.200 0.199(0.103)(0.104)(0.948)
σGX 2.000 1.887(0.155)(0.296)(0.623)
σǫ 1.414 1.571(0.050)(0.178)(0.257)
α0 -2.326 -1.366(0.838)(1.342)(0.659)
α1 0.100 0.053(0.094)(0.250)(0.901)
σGY 1.732 1.019(0.250)(0.764)(0.129)
σu 1.414 0.988(0.644)(0.526)(0.948)
Table S13: Simulations results obtained on 500 datasets with 400 families
of size 5 with at least 2 cases of a rare disease (prevalence around 1%)
and α1=0.5. Into brackets are respectively standard deviations, root mean
square errors and the coverage probabilities.
Real Value Retrospective likelihood
Est (SD) (RMSE) (Cov Pr)
β0 3.500 3.720(0.583)(0.625)(0.905)
β1 0.200 0.197(0.106)(0.110)(0.945)
σGX 2.000 1.909(0.139)(0.271)(0.625)
σǫ 1.414 1.560(0.047)(0.162)(0.245)
α0 -2.326 -1.161(0.528)(1.245)(0.311)
α1 0.500 0.287(0.221)(0.232)(0.913)
σGY 1.732 1.052(0.221)(0.715)(0.094
σu 1.414 1.009(0.501)(0.601)(0.975)
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Table S14: Simulations results obtained on 500 datasets with 400 fami-
lies of size 5 with at least 1 case of a rare disease (prevalence around 1%)
and α1=0.1. Into brackets are respectively standard deviations, root mean
square errors and the coverage probabilities.
Real Value Retrospective likelihood
Est (SD) (RMSE) (Cov Pr)
β0 3.500 3.630(0.726)(0.730)(0.909)
β1 0.200 0.200(0.104)(0.107)(0.961)
σGX 2.000 1.887(0.133)(0.266)(0.623)
σǫ 1.414 1.572(0.050)(0.176)(0.248)
α0 -2.326 -1.377(0.784)(1.339)(0.657)
α1 0.100 0.056(0.090)(0.231)(0.900)
σGY 1.732 1.010(0.231)(0.771)(0.116)
σu 1.414 0.998(0.495)(0.514)(0.761)
Table S15: Simulations results obtained on 500 datasets with 400 fami-
lies of size 5 with at least 1 case of a rare disease (prevalence around 1%)
and α1=0.5. Into brackets are respectively standard deviations, root mean
square errors and the coverage probabilities.
Real Value Retrospective likelihood
Est (SD) (RMSE) (Cov Pr)
β0 3.500 3.440(0.366)(0.467)(0.996)
β1 0.200 0.199(0.107)(0.111)(0.960)
σGX 2.000 1.892(0.108)(0.231)(0.670)
σǫ 1.414 1.4(0.045)(0.171)(0.284)
α0 -2.326 -1.453(0.472)(0.940)(0.446)
α1 0.500 0.295(0.190)(0.222)(0.948)
σGY 1.732 1.049(0.190)(0.711)(0.074)
σu 1.414 1.000(0.572)(0.494)(0.680)
Table S16: Simulations results obtained on 500 datasets with 400 families
of size 5 with at least 2 cases of a common disease (prevalence around 5%)
and α1=0.1. Into brackets are respectively standard deviations, root mean
square errors and the coverage probabilities.
Real Value Retrospective likelihood
Est (SD) (RMSE) (Cov Pr)
β0 3.500 3.500(0.822)(0.871)(0.961)
β1 0.200 0.193(0.105)(0.105)(0.951)
σGX 2.000 1.884(0.140)(0.278)(0.597)
σǫ 1.414 1.572(0.047)(0.175)(0.236)
α0 -1.644 -1.021(0.804)(1.050)(0.813)
α1 0.100 0.051(0.098)(0.230)(1.000)
σGY 1.732 1.040(0.230)(0.736)(0.131)
σu 1.414 0.987(0.517)(0.602)(0.931)
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Table S17: Simulations results obtained on 500 datasets with 400 families
of size 5 with at least 2 cases of a common disease (prevalence around 5%)
and α1=0.5. Into brackets are respectively standard deviations, root mean
square errors and the coverage probabilities.
Real Value Retrospective likelihood
Est (SD) (RMSE) (Cov Pr)
β0 3.500 3.501(0.589)(0.449)(0.996)
β1 0.200 0.186(0.107)(0.108)(0.940)
σGX 2.000 1.886(0.125)(0.246)(0.606)
σǫ 1.414 1.568(0.044)(0.168)(0.174)
α0 -1.644 -0.995(0.508)(0.767)(0.650)
α1 0.500 0.289(0.207)(0.232)(0.904)
σGY 1.732 1.054(0.207)(0.709)(0.088)
σu 1.414 1.015(0.480)(0.517)(0.910)
Table S18: Simulations results obtained on 500 datasets with 400 families
of size 5 with at least 1 case of a common disease (prevalence around 5%)
and α1=0.1. Into brackets are respectively standard deviations, root mean
square errors and the coverage probabilities.
Real Value Retrospective likelihood
Est (SD) (RMSE) (Cov Pr)
β0 3.500 3.509(0.716)(0.720)(0.921)
β1 0.200 0.197(0.106)(0.108)(0.949)
σGX 2.000 1.884(0.117)(0.254)(0.587)
σǫ 1.414 1.576(0.046)(0.178)(0.297)
α0 -1.644 -1.069(0.730)(1.078)(0.823)
α1 0.100 0.055(0.094)(0.204)(0.905)
σGY 1.732 1.036(0.204)(0.741)(0.109)
σu 1.414 0.988(0.499)(0.512)(0.724)
Table S19: Simulations results obtained on 500 datasets with 400 families
of size 5 with at least 1 case of a common disease (prevalence around 5%)
and α1=0.5. Into brackets are respectively standard deviations, root mean
square errors and the coverage probabilities.
Real Value Retrospective likelihood
Est (SD) (RMSE) (Cov Pr)
β0 3.500 3.254(0.421)(0.449)(0.982)
β1 0.200 0.196(0.107)(0.108)(0.942)
σGX 2.000 1.868(0.099)(0.226)(0.652)
σǫ 1.414 1.575(0.043)(0.175)(0.260)
α0 -1.644 -1.249(0.440)(0.540)(0.936)
α1 0.500 0.302(0.181)(0.217)(0.948)
σGY 1.732 1.044(0.181)(0.711)(0.046)
σu 1.414 1.022(0.383)(0.450)(0.770)
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Table S20: Estimates with standard deviations and RMSE of the heritability
of the secondary phenotype are given for a common disease (prevalence ≈
5%), for the four ascertainment mechanisms and two values of α1.
Ascertainment α1 Retrospective likelihood Naive method
1.At least 2 cases
0.100 0.499(0.102)(0.102) 0.17(0.08)(0.34)
0.500 0.498(0.089)(0.089) 0.19(0.08)(0.32)
2.At least 1 case
0.100 0.499(0.089)(0.089) 0.29(0.08)(0.22)
0.500 0.492(0.076)(0.077) 0.31(0.08)(0.20)
Table S21: Estimates with standard deviations and RMSE of the heritability
of the secondary phenotype are given for a rare disease (prevalence ≈ 1%),
for the four ascertainment mechanisms and two values of α1.
Ascertainment α1 Retrospective likelihood
1.At least 2 cases
0.100 0.499(0.107)(0.107))
0.500 0.505(0.104)(0.104)
2.At least 1 case
0.100 0.499(0.092)(0.092))
0.500 0.501(0.084)(0.084)
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6.1.3 Simulation study for a polygenic score
Table S22: Simulations results obtained on 500 datasets with 400 families
of size 5 with at least 2 cases of a rare disease (prevalence around 1%)
and α1=0.1. Into brackets are respectively standard deviations, root mean
square errors and the coverage probabilities.
Real Value Retrospective likelihood Naive method
Est (SD) (RMSE) (Cov Pr) Est (SD) (RMSE) (Cov Pr)
β0 3.500 3.483(0.899)(0.907)(0.899) 5.221(0.067)(1.723)(0.000)
β1 0.200 0.193(0.065)(0.073)(0.932) 0.175(0.062)(0.070)(0.922)
σGX 2.000 2.013(0.190)(0.357)(0.657) 0.990(0.146)(1.018131)(0.000)
σǫ 1.414 1.529(0.055)(0.140)(0.559) 2.467(0.025)(1.054)(0.000)
α0 -2.326 -1.932(0.921)(1.013)(0.839) -
α1 0.100 0.076(0.054)(0.069)(0.814) -
σGY 1.732 1.398(0.328)(0.548)(0.793) -
σu 1.414 1.170(0.778)(0.869)(0.920) -
Table S23: Simulations results obtained on 500 datasets with 400 families
of size 5 with at least 2 cases of a rare disease (prevalence around 1%)
and α1=0.5. Into brackets are respectively standard deviations, root mean
square errors and the coverage probabilities.
Real Value Retrospective likelihood Naive method
Est (SD) (RMSE) (Cov Pr) Est (SD) (RMSE) (Cov Pr)
β0 3.500 3.962(0.541)(0.618)(0.834) 5.178(0.069)(1.679)(0.000)
β1 0.200 0.193(0.074)(0.079)(0.940) 0.096(0.063)(0.122)(0.610)
σGX 2.000 2.084(0.165)(0.346)(0.664) 1.037(0.135)(0.972)(0.000)
σǫ 1.414 1.518(0.053)(0.130)(0.592) 2.452(0.025)(1.039)(0.000)
α0 -2.326 -1.871(0.522)(1.0314)(0.758) -
α1 0.500 0.391(0.074)(0.134)(0.772) -
σGY 1.732 1.471(0.273)(0.475)(0.796) -
σu 1.414 1.176(0.670)(0.744)(0.924) -
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Table S24: Simulations results obtained on 500 datasets with 400 fami-
lies of size 5 with at least 1 case of a rare disease (prevalence around 1%)
and α1=0.1. Into brackets are respectively standard deviations, root mean
square errors and the coverage probabilities.
Real Value Retrospective likelihood Naive method
Est (SD) (RMSE) (Cov Pr) Est (SD) (RMSE) (Cov Pr)
β0 3.500 3.338(0.573)(0.655)(0.862) 4.370(0.076)(0.850)(0.000)
β1 0.200 0.190(0.067)(0.067)(0.954) 0.189(0.066)(0.066)(0.948)
σGX 2.000 1.925(0.163)(0.364)(0.645) 1.386(0.088)(0.626)(0.000)
σǫ 1.414 1.460(0.057)(0.171)(0.676) 2.364(0.028)(0.952)(0.000)
α0 -2.326 -2.219(0.774)(0.922)(0.889) -
α1 0.100 0.073(0.058)(0.071)(0.829) -
σGY 1.732 1.359(0.307)(0.583)(0.611) -
σu 1.414 1.186(0.623)(0.714)(0.926) -
Table S25: Simulations results obtained on 500 datasets with 400 fami-
lies of size 5 with at least 1 case of a rare disease (prevalence around 1%)
and α1=0.5. Into brackets are respectively standard deviations, root mean
square errors and the coverage probabilities.
Real Value Retrospective likelihood Naive method
Est (SD) (RMSE) (Cov Pr) Est (SD) (RMSE) (Cov Pr)
β0 3.500 3.542(0.361)(0.411)(0.963) 4.346(0.076)(0.850)(0.000)
β1 0.200 0.197(0.074)(0.078)(0.944) 0.157(0.066)(0.079)(0.904)
σGX 2.000 2.018(0.127)(0.278)(0.663) 1.412(0.186)(0.600)(0.000)
σǫ 1.414 1.538(0.052)(0.147)(0.582) 2.352(0.029)(0.940)(0.000)
α0 -2.326 -1.876(0.425)(631)(0.797) -
α1 0.500 0.401(0.074)(0.128)(0.838) -
σGY 1.732 1.435(0.240)(0.473)(0.619) -
σu 1.414 1.209(0.466)(0.574)(0.948) -
Table S26: Simulations results obtained on 500 datasets with 400 families
of size 5 with at least 2 cases of a common disease (prevalence around 5%)
and α1=0.1. Into brackets are respectively standard deviations, root mean
square errors and the coverage probabilities.
Real Value Retrospective likelihood Naive method
Est (SD) (RMSE) (Cov Pr) Est (SD) (RMSE) (Cov Pr)
β0 3.500 3.370(0.854)(0.854)(0.933) 4.854(0.069)(1.356)(0.000)
β1 0.200 0.192(0.067)(0.067)(0.952) 0.177(0.063)(0.063)(0.948)
σGX 2.000 2.018(0.127)(0.278)(0.663) 1.113(0.118)(0.896)(0.000)
σǫ 1.414 1.538(0.052)(0.147)(0.682) 2.405(0.026)(0.992)(0.000)
α0 -1.644 -1.470(0.875)(0.897)(0.897) -
α1 0.100 0.073(0.057)(0.068)(0.879) -
σGY 1.732 1.477(0.295)(0.500)(0.772) -
σu 1.414 1.099(0.997)(1.139)(0.945) -
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Table S27: Simulations results obtained on 500 datasets with 400 families
of size 5 with at least 2 cases of a common disease (prevalence around 5%)
and α1=0.5. Into brackets are respectively standard deviations, root mean
square errors and the coverage probabilities.
Real Value Retrospective likelihood Naive method
Est (SD) (RMSE) (Cov Pr) Est (SD) (RMSE) (Cov Pr)
β0 3.500 3.653(0.502)(0.593)(0.932) 4.823(0.070)(1.325)(0.000)
β1 0.200 0.192(0.073)(0.075)(0.954) 0.103(0.064)(0.115)(0.656)
σGX 2.000 2.055(0.149)(0.309)(0.664) 1.148(0.113)(0.861)(0.000)
σǫ 1.414 1.530(0.051)(0.140)(0.614) 2.395(0.026)(0.982)(0.000)
α0 -1.644 -1.367(0.495)(0.599)(0.848) -
α1 0.500 0.394(0.072)(0.131)(0.868) -
σGY 1.732 1.462(0.255)(0.456)(0.762) -
σu 1.414 1.172(0.645)(0.733)(0.954) -
Table S28: Simulations results obtained on 500 datasets with 400 families
of size 5 with at least 1 case of a common disease (prevalence around 5%)
and α1=0.1. Into brackets are respectively standard deviations, root mean
square errors and the coverage probabilities.
Real Value Retrospective likelihood Naive method
Est (SD) (RMSE) (Cov Pr) Est (SD) (RMSE) (Cov Pr)
β0 3.500 3.088(0.524)(0.701)(0.896) 4.134(0.077)(0.639)(0.000)
β1 0.200 0.196(0.066)(0.0.066)(0.960) 0.193(0.066)(0.071)(0.962)
σGX 2.000 1.936(0.144)(0.364)(0.694) 1.482(0.080)(0.531)(0.000)
σǫ 1.414 1.568(0.052)(0.218)(0.607) 2.296(0.030)(0.884)(0.000)
α0 -1.644 -1.955(0.669)(0.941)(0.953) -
α1 0.100 0.077(0.056)(0.065)(0.847) -
σGY 1.732 1.444(0.285)(0.410)(0.687) -
σu 1.414 1.244(0.321)(0.415)(0.937) -
Table S29: Simulations results obtained on 500 datasets with 400 families
of size 5 with at least 1 case of a common disease (prevalence around 5%)
and α1=0.5. Into brackets are respectively standard deviations, root mean
square errors and the coverage probabilities.
Real Value Retrospective likelihood Naive method
Est (SD) (RMSE) (Cov Pr) Est (SD) (RMSE) (Cov Pr)
β0 3.500 3.278(0.341)(0.408)(0.958) 4.118(0.077)(0.623)(0.000)
β1 0.200 0.187(0.072)(0.078)(0.953) 0.159(0.067)(0.074)(0.928)
σGX 2.000 1.952(0.118)(0.285)(0.610) 1.508(0.078)(0.506)(0.004)
σǫ 1.414 1.552(0.049)(0.161)(0.607) 2.286(0.030)(0.874)(0.000)
α0 -1.644 -1.648(0.395)(0.567)(0.988) -
α1 0.500 0.392(0.071)(0.140)(0.798) -
σGY 1.732 1.373(0.230)(0.504)(0.660) -
σu 1.414 1.223(0.328)(0.337)(0.943) -
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Table S30: Estimates with standard deviations and RMSE of the heritability
of the secondary phenotype are given for a rare disease (prevalence ≈ 1%),
for the four ascertainment mechanisms and two values of α1.
Ascertainment α1 Retrospective likelihood Naive method
1.At least 2 cases
0.10 0.50(0.03)(0.13) 0.14(0.03)(0.36)
0.50 0.52(0.03)0.12) 0.15(0.03)(0.34)
2.At least 1 case
0.10 0.48(0.04)(0.12) 0.25(0.03)(0.24)
0.50 0.50(0.04)(0.10) 0.26(0.04)(0.23)
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6.2 Results analysis Leiden Longevity Study on triglyceride
levels
41
Table S31: Leiden Longevity Study: Estimates of the association between
the 41 selected SNPS and triglyceride levels for womend and for three differ-
ent approaches. The retrospective likelihood approach with same variance
assumed for the shared random effect, with different variances, and the naive
approach. Are also presented the absolute difference between the estimates
of the two last approaches with the first one. Into brackets are the standard
errors.
SNPs Constrained approach Not Constrained approach Naive Likelihood
Estimates (SE) Estimates (SE) Difference Estimates (SE) Difference
rs3863318 A .0242(.0205) .0245(.0205) .0003 .0209(.0205) .0033
rs2512139 A .0000(.0215) .0000(.0345) .0000 -.0031(.0214) .0031
rs7103514 G .0101(.0365) .0101(.0275) .0000 .0104(.0367) .0003
rs2512158 A -.0428(.0206) -.0430(.0208) .0002 -.0423(.0207) .0005
rs11216648 G .0271(.0206) .0272(.0206) .0001 .0276(.0207) .0005
rs4936414 G -.0433(.0212) -.430 (.0212) .0003 -.0429(.0213) .0004
rs4252287 A .0314(.0345) .0313(.0385) .0001 .0303(.0347) .0011
rs947889 G -.0239(.0202) -.0238(.0199) .0001 -.0241(.0203) .0002
rs2512154 A .0299(.0307) .0298(.0215) .0001 .0295(.0308) .0004
rs4936417 G .0104(.0223) .0104(.0233) .0000 .0118(.0223) .0014
rs652107 G -.0078(.0275) -.0075(.206) .0003 -.0081(.0276) .0003
rs12576767 A -.0329(.0432) -.320(.0367) .0009 -.0299(.0433) .0030
rs1786186 A -.0131(.0287) -.0132(.0216) .0001 -.0094(.0287) .0037
rs3825050 A -.0085(.0219) -.0083(.0205) .0002 -.0112(.0219) .0027
rs10160375 G -.0071(.0214) -.0072(.0203) .0001 -.0092(.0215) .0021
rs689264 A .0108(.0368) .0107(.0431) .0001 .0116(.0370) .0008
rs948461 A -.0075(.0216) -.0072(.205) .0003 -.0067(.0217) 0008
rs2276123 A -.0064(.0218) .0070(.0243) .0006 -.0090(.0218) .0026
rs948466 A .0116(.0385) .0069(.0509) .0047 .0070(.0387) .0046
rs881122 A .0149(.0243) .0149(.0217) .0000 .0169(.0244) .0020
rs2276129 A -.0012(.0217) -.0008(.0217) .0004 -.0028(.0218) .0016
rs2155857 A .0323(.0509) .0320(.0200) .0003 .0344(.0511) .0021
rs1894177 A -.0115(.0200) -.0130(.0456) .0015 -.0118(.0201) .0003
rs596134 G -.0090(.0202) -.0094(.205) .0004 -.0094(.0203) .0004
rs3741311 G .0316(.0215) .0311(.0364) .0005 .0298(.0216) .0018
rs1941637 A -.0158(.054) -.0159(.0214) .0001 -.0147(.0542) .0011
rs658624 G -.0134(.0205) -.136(.0203) .0002 -.0131(.0206) .0003
rs625464 A .0232(.0200) .0234(.286) .0002 .0236(.0200) .0004
rs11216788 A .0057(.0204) .0057(.219) .0000 .0061(.0204) .0004
rs679327 G -.0094(.0217) -.0092(.251) .0002 -.0092(.0218) .0002
rs678957 A .0061(.0457) .0053(.0209) .0008 .0066(.0459) .0005
rs7944321 A -.0238(.0252) -.0238(.0327) .0000 -.0230(.0253) .0008
rs7949751 G .0258(.0233) .0257(.0267) .0001 .0254(.0234) .0004
rs11216816 A -.0406(.0268) -.0399(.0201) .0007 -.0392(.0268) .0014
rs1805 A -.0061(.0200) -.0060(.0201) .0001 -.0056(.0201) .0005
rs3759001 A -.0101(.0205) -.103(.214) .0002 -.0098(.0206) .0003
rs4938493 C .0044(.0203) .0044(.217) .0000 .0039(.0204) .0005
rs2853009 A .0068(.0201) .0068(.0222) .0000 .0064(.0202) .0004
rs12282721 A -.0050(.0327) -.0052(.0199) .0002 -.0072(.0328) .0022
rs676134 A .0192(.0210) .0185(.0200) .0007 .0173(.0210) .0019
rs7083 A -.0570(.0205) -.0572(.0205) .0002 -.0551(.0206) .0019
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Table S32: Leiden Longevity Study: Estimates of the association between
the 41 selected SNPS and triglyceride levels for men and for three different
approaches. The retrospective likelihood approach with same variance as-
sumed for the shared random effect, with different variances, and the naive
approach. Are also presented the absolute difference between the estimates
of the two last approaches with the first one. Into brackets are the standard
errors.
SNPs Constrained approach Not Constrained approach Naive Likelihood
Estimates (SE) Estimates (SE) Difference Estimates (SE) Difference
rs3863318 A .0511(.0236) .0501(.0236) .0010 .0494(.0236) .0017
rs2512139 A .0294(.0249) .0285(.0249) .0009 .0294(.0249) .0000
rs7103514 G -.0329(.0426) -.0324(.0427) .0005 -.0332(.0426) .0003
rs2512158 A .0119(.0241) .0118(.0241) .0001 .0116(.0241) .0003
rs11216648 G -.0121(.0244) -.0124(.0244) .0003 -.0114(.0244) .0007
rs4936414 G .0161(.0244) .0162(.0245) .0001 .0161(.0244) .0000
rs4252287 A .0624(.0386) .0631(.0386) .0007 .0620(.0386) .0004
rs947889 G .0343(.0237) .0335(.0238) .0008 .0335(.0237) .0008
rs2512154 A .0458(.0351) .0444(.0353) .0014 .0453(.0352) .0009
rs4936417 G .0280(.0256) .0280(.0256) .0000 .0283(.0256) .0003
rs652107 G -.0562(.0310) -.0568(.0311) .0006 -.0579(.0310) .0017
rs12576767 A -.0087(.0468) -.0086(.0472) .0001 -.0080(.0469) .0007
rs1786186 A -.0755(.0356) -.0748(.0357) .0007 -.0736(.0357) .0019
rs3825050 A .0178(.0250) .0182(.0252) .0004 .0177(.0251) .0001
rs10160375 G .0172(.0248) .0172(.0249) .0000 .0170(.0248) .0002
rs689264 A -.0549(.0466) -.0549(.0465) .0000 -.0536(.0466) .0013
rs948461 A .0360(.0249) .0352(.025) .0008 .0360(.0249) .0000
rs2276123 A .0121(.0253) .0121(.0253) .0000 .0121(.0253) .0000
rs948466 A -.0493(.0498) -.0491(.0499) .0002 -.0470(.0499) .0023
rs881122 A -.0519(.0280) -.0523(.028) .0004 -.0526(.0280) .0007
rs2276129 A .0161(.0250) .0161(.0251) .0000 .0162(.0250) .0001
rs2155857 A .0473(.0633) .0482(.0634) .0009 .0526(.0633) .0053
rs1894177 A .0267(.0232) .0263(.0233) .0004 .0273(.0232) .0006
rs596134 G .0164(.0238) .0160(.0238) .0004 .0172(.0238) .0008
rs3741311 G -.0054(.0247) -.0052(.0248) .0002 -.0046(.0247) .0008
rs1941637 A .0888(.0667) .0897(.0668) .0011 .0921(.0667) .0033
rs658624 G .0235(.0239) .0232(.0239) .0003 .0247(.0239) .0012
rs625464 A -.0245(.0239) -.0241(.024) .0004 -.0249(.0240) .0004
rs11216788 A .0575(.0239) .0572(.024) .0003 .0579(.0240) .0004
rs679327 G -.0622(.0270) -.0623(.0271) .0001 -.0621(.0270) .0001
rs678957 A -.0756(.0583) -.0768(.0585) .0012 -.0761(.0583) .0005
rs7944321 A -.1010(.0315) -.1012(.0315) 0002 -.1008(.0315) .0002
rs7949751 G -.0311(.0270) -.0310(.027) .0001 -.0303(.0270) .0008
rs11216816 A -.0334(.0330) -.0333(.033) .0001 -.0331(.0330) .0003
rs1805 A -.0430(.0243) -.0428(.0243) .0002 -.0427(.0243) .0003
rs3759001 A -.0408(.0241) -.0406(.0242) .0002 -.0407(.0241) .0001
rs4938493 C .0377(.0236) .0377(.0237) .0000 .0379(.0236) .0002
rs2853009 A .0184(.0234) .0184(.0234) .0000 .0187(.0234) .0003
rs12282721 A -.0532(.0379) -.0534(.038) .0002 -.0523(.0379) .0009
rs676134 A -.0236(.0243) -.0234(.0244) .0002 -.0233(.0243) .0003
rs7083 A .0228(.0244) .0229(.0245) .0001 .0221(.0244) .0007
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Figure S2: Estimates for the association of 41 SNPs with triglyceride in the
LLS. In the top and bottom are the estimates of the 41 SNPs for women and
for men respectively. The black line represents no SNP effect on triglyceride.
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